Stock Market Mentor

Watch BioTech for a fresh breakout $XBI – August 26, 2026

Scott McGregor
Read the transcript
print

Key Takeaways

  • Sustained Sector Uptrend: The XBI Biotech ETF has maintained a strong, persistent uptrend since April of last year.

  • Proven Buyer Support: Dip buyers consistently step in when the ETF pulls under key moving averages, pushing price action back above support.

  • Breakout Trigger Level: A move through and close above 169.70 serves as the primary near-term buying trigger.

  • Defined Swing Risk: Near-term support at 161.00 and the 8-day EMA offer a logical, low-risk stop-loss location for a swing trade.

Riding the Sector Wave: Trading the XBI Biotech ETF Breakout

Finding persistent, institutional trend strength in broad equity markets requires looking for sectors that consistently bounce off technical support. The biotechnology sector stands out as a prime example of sustained relative strength.

As market technician Scott McGregor points out, the SPDR S&P Biotech ETF (Ticker: XBI) is coiling just beneath historic record territory, establishing a high-probability swing trade setup.

Technical Pattern Analysis

Since April of last year, the XBI Biotech ETF has respected its primary moving average ribbons. Even when short-term pullbacks push price underneath key moving averages, institutional buyers quickly step in to close daily candles back above short-term momentum lines.

Recently, price action tested support near 161.00, held the 8-day exponential period moving average (EMA), and rallied directly toward its prior all-time high.

Framing the Swing Entry

To trade this technical continuation cleanly:

  • The Breakout Trigger: Stalk a high-volume move through and above 169.70 to confirm that buyers are driving price into new high territory.

  • The Position Strategy: Use this trigger either to add size to an existing winning tranche or to open a fresh swing trade.

  • The Invalidation Floor: Anchor your protective stop-loss down around 161.00 near the 8-day EMA.

By waiting for price action to clear 169.70 and anchoring risk to 161.00, traders can systematically participate in the ongoing momentum of the biotech sector.